• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GUIDANT CRM CLONMEL IRELAND TELIGEN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GUIDANT CRM CLONMEL IRELAND TELIGEN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR Back to Search Results
Model Number E110
Device Problems Device Alarm System (1012); High impedance (1291); Device Displays Incorrect Message (2591); Ambient Noise Problem (2877)
Patient Problems Syncope (1610); Fall (1848); Bone Fracture(s) (1870); Ventricular Tachycardia (2132)
Event Date 10/01/2017
Event Type  malfunction  
Manufacturer Narrative
The local area sales representative was contacted for additional information.At this time, no further information is available.Should additional information become available this report will be updated.
 
Event Description
Boston scientific received information that the patient implanted with this implantable cardioverter defibrillator (icd) and right ventricular (rv) defibrillation lead experienced a syncopal episode, fell and broke an ankle approximately 4 months ago.The patient reported that the device had been emitting beeping tones ever since.Review of stored device memory during a routine in clinic device follow up noted the device recorded a shock lead open message that correlated with a stored ventricular tachycardia (vt) episode and syncope.The device appropriate detected and delivered anti-tachycardia pacing (atp) and shock therapy, which, slowed the rhythm.High out of range shock impedance measurements greater than 125 ohms were recorded with shock delivery and resulted in the beeping tones.Review of daily measurements noted a gradual increase in shock impedance measurements with intermittent out of range measurements approximately beginning 6 months ago.Farfield signals from the rv were observed on the right atrial (ra) channel, however, were appropriately blanked.Boston scientific technical services (ts) discussed that shock therapy may not be effective with the high shock impedance measurements and discussed the option of replacing the lead.No additional adverse patient effects were reported.This product remains implanted and in service.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TELIGEN
Type of Device
IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
Manufacturer (Section D)
GUIDANT CRM CLONMEL IRELAND
guidant ireland
clonmel, tipperary ireland
Manufacturer (Section G)
GUIDANT CRM CLONMEL IRELAND
guidant ireland
clonmel, tipperary ireland
Manufacturer Contact
tim degroot
4100 hamline ave. n
st. paul, MN 
6515826168
MDR Report Key7615311
MDR Text Key111645285
Report Number2124215-2018-07885
Device Sequence Number1
Product Code LWP
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation Health Professional
Type of Report Initial
Report Date 04/11/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Lay User/Patient
Device Expiration Date05/28/2010
Device Model NumberE110
Other Device ID NumberTELIGEN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? Yes
Initial Date Manufacturer Received 04/11/2018
Initial Date FDA Received06/19/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured06/04/2009
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age65 YR
-
-